Patent SG-11201908088R-A (SG)
Title: Antibodies against pd-l1
Inventor: ALTINTAS ISIL
IPC: C07K16/10
Filed: 2018-03-09
Abstract: INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 13 September 2018 (13.09.2018) WIP0 I PCT onion °noI0 OilIIIII010010 1111111 Oil ow (10) International Publication Number WO 2018/162749 Al (51) International Patent Classification: C07K 16/10 (2006.01) C07K 16/28 (2006.01) (21) International Application Number: PCT/EP2018/055977 (22) International Filing Date: 09 March 2018 (09.03.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: PA 2017 00164 09 March 2017 (09.03.2017) DK PA 2017 00408 11 July 2017 (11.07.2017) DK (71) Applicant: GENMAB A/S [DK/DK]; Kalvebod Brygge 43, 1560 Copenhagen V (DK). (72) Inventors: ALTINTAS, Isil; c/o Genmab B.V., Upp- salalaan 15, 3584 CT Utrecht (NL). SATIJN, David; c/ o Genmab B.V., Uppsalalaan 15, 3584 CT Utrecht (NL). VAN DEN BRINK, Edward; c/o Genmab B.V., Upp- salalaan 15, 3584 CT Utrecht (NL). VERZIJL, Dennis; c/ o Genmab B.V., Uppsalalaan 15, 3584 CT Utrecht (NL). RADEMAKER, Rik; c/o Genmab B.V., Uppsalalaan 15, 3584 CT Utrecht (NL). PARREN, Paul; Werdorperwaard 17, 3984 PR Odijk (NL). DE GOEIJ, Bart; c/o Genmab B.V., Uppsalalaan 15, 3584 CT Utrecht (NL). TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) with sequence listing part of description (Rule 5.2(a)) W O 20 18/ 16 27 49 Al (74) Agent: GENMAB A/S; Kalvebod Brygge 43, 1560 Copen- hagen V (DK). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, (54) Title: ANTIBODIES AGAINST PD-L1 (57) : The present invention relates to novel antibodies and their use in medicine. In particular, the invention relates to bispecific antibodies capable of binding human PD-L1 and capable of binding human CD3. Novel classes of antibodies capable of binding human PD-L1 are also provided. The invention furthermore relates to uses of the antibodies of the invention and to methods, nucleic acid constructs and host cells for producing antibodies of the invention.